• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一名接受环磷酰胺治疗的患者发生气肿性膀胱炎。

Emphysematous Cystitis in a Patient Receiving Cyclophosphamide.

作者信息

Al Zein Said

机构信息

Department of Medicine, University of Pittsburgh, Pittsburgh, USA.

出版信息

Cureus. 2021 Oct 12;13(10):e18722. doi: 10.7759/cureus.18722. eCollection 2021 Oct.

DOI:10.7759/cureus.18722
PMID:34790477
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8583972/
Abstract

Emphysematous cystitis (EC) is a form of complicated urinary tract infection (UTI) well described in patients with diabetes. Other known risk factors include urinary tract obstruction, older age, and female gender. This case describes a patient who developed emphysematous cystitis while receiving induction therapy with intravenous cyclophosphamide to treat antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis that presented with rapidly progressive glomerulonephritis (RPGN). The association between cyclophosphamide therapy and emphysematous cystitis has only been reported twice in literature.

摘要

气肿性膀胱炎（EC）是糖尿病患者中一种描述详尽的复杂性尿路感染（UTI）形式。其他已知的风险因素包括尿路梗阻、高龄和女性。本病例描述了一名患者，该患者在接受静脉注射环磷酰胺诱导治疗以治疗表现为快速进展性肾小球肾炎（RPGN）的抗中性粒细胞胞浆抗体（ANCA）相关性血管炎时发生了气肿性膀胱炎。环磷酰胺治疗与气肿性膀胱炎之间的关联在文献中仅被报道过两次。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc86/8583972/7b9312db4540/cureus-0013-00000018722-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc86/8583972/879bdcf3d076/cureus-0013-00000018722-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc86/8583972/7b9312db4540/cureus-0013-00000018722-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc86/8583972/879bdcf3d076/cureus-0013-00000018722-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc86/8583972/7b9312db4540/cureus-0013-00000018722-i02.jpg

相似文献

1
Emphysematous Cystitis in a Patient Receiving Cyclophosphamide.一名接受环磷酰胺治疗的患者发生气肿性膀胱炎。
Cureus. 2021 Oct 12;13(10):e18722. doi: 10.7759/cureus.18722. eCollection 2021 Oct.
2
Antineutrophil cytoplasmic antibody (ANCA) and rapidly progressive crescentic glomerulonephritis in Thai population.泰国人群中的抗中性粒细胞胞浆抗体（ANCA）与急进性新月体性肾小球肾炎
Asian Pac J Allergy Immunol. 1999 Dec;17(4):281-7.
3
Improvements in treatment strategies for patients with antineutrophil cytoplasmic antibody-associated rapidly progressive glomerulonephritis.抗中性粒细胞胞浆抗体相关快速进展性肾小球肾炎患者治疗策略的改进
Ther Apher Dial. 2006 Oct;10(5):390-5. doi: 10.1111/j.1744-9987.2006.00401.x.
4
Encrusting cystitis due to Corynebacterium urealyticum in a patient with ANCA-associated vasculitis: case report and review of the literature.尿素分解支原体致抗中性粒细胞胞质抗体相关性血管炎患者的结石性膀胱炎：病例报告及文献复习。
Semin Arthritis Rheum. 2011 Oct;41(2):297-300. doi: 10.1016/j.semarthrit.2010.11.004. Epub 2011 Feb 1.
5
Concurrent Bilateral Emphysematous Pyelonephritis and Emphysematous Cystitis: A Case Report of Glomerulonephritis Severe Complication.双侧气肿性肾盂肾炎和气肿性膀胱炎并存：1例肾小球肾炎严重并发症的病例报告
Res Rep Urol. 2021 Jun 21;13:375-379. doi: 10.2147/RRU.S315755. eCollection 2021.
6
[Emphysematous cystitis in a patient with type-1diabetes mellitus - diagnostic difficulties].1型糖尿病患者的气肿性膀胱炎——诊断困难
Wiad Lek. 2018;71(7):1424-1428.
7
Emphysematous cystitis revealed by necrotizing fasciitis: An unusual presentation.坏死性筋膜炎揭示的气肿性膀胱炎：一种不寻常的表现。
Urol Case Rep. 2023 Jan 11;46:102326. doi: 10.1016/j.eucr.2023.102326. eCollection 2023 Jan.
8
Treatment of antineutrophil cytoplasmic autoantibody-positive systemic vasculitis and glomerulonephritis with pooled intravenous gammaglobulin.用静脉注射丙种球蛋白治疗抗中性粒细胞胞浆自身抗体阳性的系统性血管炎和肾小球肾炎。
Am J Kidney Dis. 1992 Nov;20(5):504-8. doi: 10.1016/s0272-6386(12)70265-2.
9
Dual myeloperoxidase-antineutrophil cytoplasmic antibody- and antiglomerular basement membrane antibody-positive cases associated with prior pulmonary fibrosis: a report of four cases.双重髓过氧化物酶-抗中性粒细胞胞质抗体和抗肾小球基底膜抗体阳性病例与先前的肺纤维化相关：4 例报告。
Clin Exp Nephrol. 2011 Apr;15(2):226-34. doi: 10.1007/s10157-010-0390-0. Epub 2011 Jan 20.
10
A Rare Case of Double Antibody-Positive Rapidly Progressive Glomerulonephritis: A Therapeutic Challenge.一例罕见的双抗体阳性急进性肾小球肾炎：治疗挑战。
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211013193. doi: 10.1177/23247096211013193.

引用本文的文献

1
Urotoxicity of Cyclophosphamide: A Comparison Across Neoplastic, Autoimmune, and Transplant Indications.环磷酰胺的尿路毒性：肿瘤、自身免疫性疾病及移植适应症的比较
Cureus. 2024 Dec 5;16(12):e75180. doi: 10.7759/cureus.75180. eCollection 2024 Dec.

本文引用的文献

1
Emphysematous cystitis: A case report and literature review of 113 cases.气肿性膀胱炎：113例病例报告及文献综述
Urol Ann. 2021 Jul-Sep;13(3):312-315. doi: 10.4103/UA.UA_61_20. Epub 2021 Jun 23.
2
Incidence of hemorrhagic cystitis after cyclophosphamide therapy with or without mesna: A cohort study and comprehensive literature review.环磷酰胺联合或不联合美司钠治疗后出血性膀胱炎的发生率：一项队列研究和全面的文献复习。
J Oncol Pharm Pract. 2021 Mar;27(2):340-349. doi: 10.1177/1078155220920690. Epub 2020 May 1.
3
Emphysematous cystitis: a review of 135 cases.
气肿性膀胱炎：135例病例回顾
BJU Int. 2007 Jul;100(1):17-20. doi: 10.1111/j.1464-410X.2007.06930.x. Epub 2007 May 17.
4
Emphysematous cystitis: possible side-effect of cyclophosphamide therapy.
Clin Nephrol. 1998 Dec;50(6):394-6.
5
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--I. Experimental studies on the urotoxicity of alkylating compounds.氮杂磷三环类细胞抑制剂的尿路毒性及其预防研究——I. 烷基化化合物尿路毒性的实验研究
Eur J Cancer (1965). 1981 Jun;17(6):595-607. doi: 10.1016/0014-2964(81)90261-9.
6
Gas gangrene of the bladder complicating cyclophosphamide cystitis.
Br J Urol. 1984 Feb;56(1):100-1. doi: 10.1111/j.1464-410x.1984.tb07176.x.
7
Cystitis emphysematosa.气肿性膀胱炎
Urology. 1974 May;3(5):612-4. doi: 10.1016/s0090-4295(74)80259-1.
8
Mixed acid fermentation of glucose as a mechanism of emphysematous urinary tract infection.葡萄糖的混合酸发酵作为气肿性尿路感染的一种机制。
J Urol. 1991 Jul;146(1):148-51. doi: 10.1016/s0022-5347(17)37736-4.